A randomised clinical trial investigating the effect of pembrolizumab versus nil in
Studied treatment | |
Control treatment |
Patients | |
Group sizes | -9 / -9 |
Blindness | Inclusion period | ||
Follow-up duration | Centers | ||
Lost to FU | geographical localisation | ||
Primary endpoint | Design | Single-arm study |
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Ros Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013 [PMID: 29543932] link to pdf add to Mendeley
Links
ClinicalTrial.gov record NCT02335411
Appears in following systematic reviews: